Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data.
about
Advancing human health risk assessment: integrating recent advisory committee recommendationsIPCS framework for analyzing the relevance of a noncancer mode of action for humansCritical role of toxicologic pathology in a short-term screen for carcinogenicityApproaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric populationDeveloping and applying the adverse outcome pathway concept for understanding and predicting neurotoxicityAssessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humansPerspectives on validation of high-throughput assays supporting 21st century toxicity testingApplication of the U.S. EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromiumCreating context for the use of DNA adduct data in cancer risk assessment: I. Data organization.Adverse Outcome Pathways as Tools to Assess Drug-Induced Toxicity.The Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds.Evaluation of the carcinogenicity of inorganic arsenic.Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence.Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inferenceSuccessful drug development despite adverse preclinical findings part 1: processes to address issues and most important findingsRelationship of metabolism and cell proliferation to the mode of action of fluensulfone-induced mouse lung tumors: analysis of their human relevance using the IPCS framework.Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.Consideration of rat chronic progressive nephropathy in regulatory evaluations for carcinogenicity.Characterization of diversity in toxicity mechanism using in vitro cytotoxicity assays in quantitative high throughput screening.Key Elements for Judging the Quality of a Risk Assessment.Carcinogenic mode of action of folpet in mice and evaluation of its relevance to humans.Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview.A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens.Hypothesis-based weight-of-evidence evaluation of the neurodevelopmental effects of chlorpyrifos.A review of the mode of toxicity and relevance to humans of the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-1,3-cyclohexanedione.A survey of frameworks for best practices in weight-of-evidence analyses.Dose-response approaches for nuclear receptor-mediated modes of action for liver carcinogenicity: Results of a workshop.New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis.Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study.Mode of action and dose-response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study.Diuron-induced rat urinary bladder carcinogenesis: mode of action and human relevance evaluations using the International Programme on Chemical Safety framework.In vitro and modelling approaches to risk assessment from the U.S. Environmental Protection Agency ToxCast programme.Application of a novel integrated toxicity testing strategy incorporating "3R" principles of animal research to evaluate the safety of a new agrochemical sulfoxaflor.Human relevance framework for rodent liver tumors induced by the insecticide sulfoxaflor.Mode-of-action and human relevance framework analysis for rat Leydig cell tumors associated with sulfoxaflor.Human relevance framework evaluation of a novel rat developmental toxicity mode of action induced by sulfoxaflor.The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events.European Union's strategy on endocrine disrupting chemicals and the current position of Slovenia.Relationship of Metabolism and Cell Proliferation to the Mode of Action of Fluensulfone-Induced Mouse Lung Tumors. II: Additional Mechanistic Studies.Editor's Highlight: Analysis of the Effects of Cell Stress and Cytotoxicity on In Vitro Assay Activity Across a Diverse Chemical and Assay Space.
P2860
Q27013780-E97A8FF2-5267-485D-B8C7-938914D2849CQ27921844-AC5D09E6-D0F1-4B00-B5B8-236015698709Q28075960-823730D8-EEB8-4111-8ABA-5239435FADC8Q28389663-04C4F86A-CB64-49C0-91B4-809DE0EB32CFQ28394433-FD1D5C71-3349-4D9F-ABB6-835030F7D71DQ28396010-16DB890E-FC89-4C16-BE22-56757957E680Q28658651-79B48CFC-F3D1-463E-9C92-E6197464CDEAQ28744112-AD6CB2D4-1901-49C1-AB5E-139809CFD054Q33501831-2945F77D-6570-4369-972E-9D73F01DF8AEQ33703437-7AD365B0-5891-4136-A787-870944E0203FQ33736240-C235D006-7A92-4FAD-A9C0-8879D183F628Q34371580-5D1BED1D-2787-40F4-8BA8-42290516EFF0Q35062017-ECB3C0E9-3C49-4AD0-9D8A-071E0A3EB072Q35161424-63C34166-592E-47C1-9990-B9902AB12741Q35603973-DD7A0969-47ED-4403-828B-21452ACF5C81Q36080030-2A4A38D6-D1C2-4D79-9166-F508FB3D5894Q36093316-788EF2CC-44FB-4764-96CA-0CB657127F70Q36678470-9C2D96DA-49FB-48D8-AB38-283108038293Q37156560-7EBFCC25-C6CD-48DB-BF22-C7AA0A008A99Q37158828-A1D3B788-6731-48F3-B1D8-A38F90441092Q37762534-63A0A94C-2B2E-4627-9313-6B7EEFB266E2Q37852707-F2C6794C-7053-4232-9677-C80B9C9AF0A4Q37876891-FBC3BAF4-1A7B-4946-BE83-2C9CE76492C9Q37956375-8F770846-91D4-4B75-9248-BC3276CCD209Q38080895-A58F4D8D-DA23-432B-A767-0A2FBBCD022CQ38138160-D6080E6D-A79A-4652-B86F-69D2B726D1DBQ38148198-7AB9F014-99D6-46BA-9F89-DB28A34804ADQ38156062-9D9FB275-5C2E-42BC-BC63-FF6C72909432Q38158164-F43909B9-163D-4216-85F0-22FD602B82F9Q38163594-C55A5C70-85E0-4A0F-9302-84BE2D56178EQ38186798-281977EB-AD35-4679-A2CC-60644AB4281CQ38200703-8F013D21-BE44-4441-AEE9-FF083023A5E1Q38212104-3D541E9B-E583-4B13-B2D9-E0B2A3118C54Q38212105-D2BCF746-8A90-491B-8863-386C6E0EC865Q38212106-6F39E4C8-3286-4D11-ACEA-842FEE664DD1Q38212107-2ABCD2D0-F373-4F52-B182-0702A9D05222Q38234794-EF0C65B7-A49F-4CAF-930E-E3BFD20F33CCQ38872937-C74170B8-22DE-42DE-BE53-0DF8855100FFQ39412227-FF3F54B1-D3E1-4BF5-91CC-9DB3EE9CE4DFQ39747696-D0F45A8C-7A3F-41BB-BF76-E850D26BB40C
P2860
Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Overview: Using mode of action ...... vance of animal toxicity data.
@ast
Overview: Using mode of action ...... vance of animal toxicity data.
@en
type
label
Overview: Using mode of action ...... vance of animal toxicity data.
@ast
Overview: Using mode of action ...... vance of animal toxicity data.
@en
prefLabel
Overview: Using mode of action ...... vance of animal toxicity data.
@ast
Overview: Using mode of action ...... vance of animal toxicity data.
@en
P2093
P2860
P1476
Overview: Using mode of action ...... vance of animal toxicity data.
@en
P2093
Dorothy E Patton
Edward W Carney
Gary Kimmel
Gary M Williams
James Klaunig
Jeanette Wiltse
Jennifer Seed
John M DeSesso
Paul M D Foster
P2860
P304
P356
10.1080/10408440591007133
P407
P577
2005-10-01T00:00:00Z